TRINETRA › Sectors › Healthcare
SMS Pharmaceuticals Limited (SMSPHARMA) — share price, P/E and fundamentals
SMS Pharmaceuticals Limited (NSE: SMSPHARMA) closed at ₹511.35 on 30 Oct 2026, +74.5% over one year, against a 52-week range of ₹270.10 – ₹525.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 31 Jul 2026) it reported revenue of ₹207 cr and net profit of ₹21 cr, a 10.1% net margin; revenue grew 5.6% and profit grew 11.6% year on year.
On four consecutive filed quarters its trailing P/E is 46.6; since 30 May 2025 its own P/E has ranged from 26.3 to 45.5 (median 35.3), and today's reading is higher than 100% of those 350 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 10.6%, ROCE 13.0%, debt-to-equity 0.46, Piotroski F-score 6 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 25% of 64 sector peers; PBT margin higher than 27% of 64 sector peers; ROE higher than 28% of 64 sector peers.
Key figures
| Last close | ₹511.35 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +7.9% / +28.9% / +74.5% |
| 52-week low – high | ₹270.10 – ₹525.00 |
| Market capitalisation | ₹4,789 cr |
| Trailing P/E | 46.6 |
| Price / book | 6.09 |
| EV / EBITDA | 28.0 |
| Earnings yield | 2.1% |
| TTM EPS | ₹10.97 |
| TTM net profit | ₹103 cr |
| Quarter revenue | ₹207 cr |
| Quarter net profit | ₹21 cr |
| Net margin | 10.1% |
| Revenue growth (YoY) | +5.6% |
| Profit growth (YoY) | +11.6% |
| Return on equity | 10.6% |
| ROCE | 13.0% |
| Debt / equity | 0.46 |
| Current ratio | 1.81 |
| Free cash flow | ₹-71 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹15.1 cr |
Against Healthcare peers
| Metric | SMSPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.10 | 12.89 | 25 |
| PBT margin | 13.14 | 17.68 | 27 |
| ROE | 10.64 | 13.87 | 28 |
| ROCE | 12.96 | 17.26 | 27 |
| Debt / equity | 0.46 | 0.11 | 88 |
| Cash conversion | 0.58 | 1.25 | 15 |
| Trailing P/E | 46.63 | 43.26 | 53 |
| P/B | 6.09 | 6.02 | 53 |
Questions
What is the P/E ratio of SMS Pharmaceuticals Limited?
SMS Pharmaceuticals Limited's trailing P/E is 46.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 30 May 2025 its P/E has ranged 26.3–45.5.
What were SMS Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, SMS Pharmaceuticals Limited reported revenue of ₹207 cr and net profit of ₹21 cr (consolidated), filed with the exchange on 31 Jul 2026.
What is SMS Pharmaceuticals Limited's ROE?
Return on equity is 10.6% based on the balance sheet dated 31 Mar 2026.
Does SMS Pharmaceuticals Limited have debt?
Debt-to-equity is 0.46 on the balance sheet dated 31 Mar 2026.
What is SMSPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SMSPHARMA traded between ₹270.10 and ₹525.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.